Geron Corporation (GERN) AI Stock Analysis

Geron Corporation is a late-stage clinical biopharmaceutical company dedicated to advancing therapeutics aimed at myeloid hematologic malignancies. Founded in 1990 and headquartered in Foster City, California, the company focuses on telomere biology and therapeutic development. At the forefront of its portfolio is imetelstat, a telomerase inhibitor in Phase 3 clinical trials designed to target the uncontrolled proliferation of malignant stem and progenitor cells. Geron is developing imetelstat for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis, collaborating with leading experts and institutions to address critical medical needs in oncology.

Geron's revenue expanded from $1.4M in FY2021 to $183.9M in FY2025, delivering a 5-year revenue CAGR of 273.5% from FY2020 to FY2025. Annual top-line growth accelerated sharply by 32386.9% in FY2024 to $77.0M and by 138.8% in FY2025. Net losses have narrowed from -$184.1M in FY2023 to -$85.8M in FY2025, improving EPS from -$0.33 to -$0.10. For FY2025, gross margin remained high at 97.4%, while operating margin was -29.3%. For the latest quarter ended June 30, 2026, quarterly revenue grew 17.2% year-over-year, bringing trailing twelve month revenue to $204.6M with a profit margin of -33.1% and EPS of -$0.11.

As of June 30, 2026, Geron held $300.8M in cash and short-term investments and $122.1M in total debt, yielding net cash of $178.7M. Total assets stood at $519.0M against shareholders' equity of $218.6M. The company shows solid liquidity with a current ratio of 6.92 and a debt-to-equity ratio of 0.56. Operating cash flow was -$111.0M and free cash flow was -$111.1M in FY2025, accompanied by capital expenditures of $49,000. Additionally, the share count increased 102.7% over 5 years.

Geron trades at a market capitalization of $751.7M and an enterprise value of $659.7M. Its forward P/E ratio is 65.4x, which is elevated compared to the 17.3x median of its US-listed Healthcare peers. The company's price-to-sales ratio of 3.7x and EV-to-revenue ratio of 3.2x compare to a peer median price-to-sales of 4.1x. Over the past year, Geron's stock fell 4.9%, while the S&P 500 (SPY) returned 16.8%. Over a 5-year period, the stock declined 17.0% compared to an 83.0% return for the benchmark index.

Wall Street coverage includes 3 Strong Buy, 1 Buy, and 1 Hold rating, with zero Sell or Strong Sell ratings. The mean price target of $4.25 represents an upside of 263.2% from the last close of $1.17. For the fiscal year ending December 31, 2026, analysts estimate revenue of $236.3M and an EPS of -$0.02. For FY2027, the consensus projects $342.0M in revenue and positive EPS of $0.04. Geron has beaten EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of Geron Corporation (GERN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GERN income statement, GERN balance sheet, GERN key metrics, GERN analyst forecast, GERN chart. See the GERN stock overview for the latest quote and news.